New research reveals that patients who discontinue new GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who halt conventional diet and exercise plans.
Research printed in a major medical journal demonstrates that while overweight people often shed substantial amounts of their total mass while using the jabs, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"Users purchasing such drugs must be cognizant of the potential of fast rebound weight gain when the therapy is stopped," warns expert Dr. Susan Jebb.
Such speed of recovery implies a reversion to pre-treatment weight in about 18 months.
Weighing Approaches
The analysis, which reviewed 37 of trials involving over 9,000 of patients, contrasted the effects of these new drugs with older methods.
Scientists note that individuals who lose weight through diet and exercise usually see a more gradual weight regain—approximately 0.1 kg a month—after stopping.
Understanding the Rapid Rebound
Nutrition scientists propose the mode of action of the jabs accounts for the heightened rebound.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production could lead to the system to produce less of its endogenous GLP-1, and may also lessen responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication means appetite is no longer kept in check, making binge eating a significant risk."
An Ongoing Issue?
Medical guidelines suggest the jabs for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Professionals say that, given the significant potential of relapse, the therapy is often life-long.
This opinion is supported by pharmaceutical companies, who note that the findings "underscore the long-term nature of obesity," akin to managing conditions like high blood pressure.
Patient Accounts
Users who have discontinued the jabs explain a sudden resurgence of hunger.
"It was like something activating and I was suddenly starving," described a patient.
This challenge is worsened if patients have not adopted permanent dietary or behavioural modifications during therapy.
Widespread Use
Recent estimates indicate that a significant number of people in the UK have tried these injections in the past year, with demand continuing to grow.
- Use is more common among females compared to men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
Ultimately, clinicians emphasize that while the jabs are potent agents for shedding pounds, they are not a standalone cure and maintained weight loss relies on combined behavioural changes.
